AtheroGenics, Inc.
Inflammatory diseases drug maker reports quarterly loss of $0.43 per share
Published in Pharma Investments, Ventures and Law Weekly, March 14th, 2004
For the fourth quarter ended December 31, 2003, AtheroGenics incurred a net loss of $15.8 million, or $0.43 per share, compared to a net loss of $7.9 million, or $0.28 per share, for the fourth quarter of 2002. For the 12 months ended December 31, 2003, AtheroGenics reported a net loss of $53.3 million, or $1.49 per share, compared to a net loss of $28.0 million, or $1.00 per share, for the 12 months ended December 31, 2002.
The increased net loss in 2003...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Abiomed, Inc.
Product revenues increase 17% for cardiovascular device maker - Acuity Pharmaceuticals
Ophthalmic pharmaceutical company announces completion of financing round - Advancis Pharmaceutical Corp.
Pharmaceutical company reports loss of $0.29 per share - Alaris Medical Systems, Inc.
Drug delivery company's debt upgraded by Moody's - Alcon, Inc.
Sales grow 13.7% for pharmaceutical company - Alexion Pharmaceuticals, Inc.
Boess named VP, chief financial officer at pharmaceutical firm - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
